<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Peter G. Traber, M.D. on Medium]]></title>
        <description><![CDATA[Stories by Peter G. Traber, M.D. on Medium]]></description>
        <link>https://medium.com/@petertraber?source=rss-845d7f332ac4------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*zGq0s72VpAnmHjFlWxfaWg.jpeg</url>
            <title>Stories by Peter G. Traber, M.D. on Medium</title>
            <link>https://medium.com/@petertraber?source=rss-845d7f332ac4------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 23:34:11 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@petertraber/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[US Liver Transplantation Rates on the Rise in Baby Boomers with NASH]]></title>
            <link>https://medium.com/the-liver-line/us-liver-transplantation-rates-on-the-rise-in-baby-boomers-with-nash-9733a657554b?source=rss-845d7f332ac4------2</link>
            <guid isPermaLink="false">https://medium.com/p/9733a657554b</guid>
            <category><![CDATA[health]]></category>
            <category><![CDATA[baby-boomers]]></category>
            <category><![CDATA[fatty-liver]]></category>
            <category><![CDATA[liver-transplant]]></category>
            <category><![CDATA[nash]]></category>
            <dc:creator><![CDATA[Peter G. Traber, M.D.]]></dc:creator>
            <pubDate>Wed, 08 Nov 2017 14:05:59 GMT</pubDate>
            <atom:updated>2018-07-25T19:06:51.747Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*n2Rhsbez4poMS-rqUwuj8g.jpeg" /></figure><p>According to a <a href="http://www.xiahepublishing.com/ArticleFullText.aspx?sid=2&amp;jid=1&amp;id=10.14218%2FJCTH.2017.00003">study published in the Journal of Clinical and Translational Hepatology</a>, the liver transplantation rate due to Nonalcoholic Steatohepatitis (NASH) is rising in the United States and the baby boomer generation is mainly responsible for this alarming trend as a high risk patient population.</p><p>NASH is the most rapidly growing indication for liver transplantation and is on the trajectory to overcome Hepatitis C as the leading indication in the next decade. Due to the rise in obesity rates in the US and globally over the last two decades, the prevalence of NASH has increased, particularly in the baby boomer generation. Researchers recognize these trends present the medical community with a management challenge in liver evaluation in an aging population with increasing prevalence of diabetes.</p><p>Due to the asymptomatic nature of NASH, researchers suggest in order to halt the disease’s detrimental impact, community awareness efforts on prevention measures, education across all levels of healthcare on early detection and diagnosis, and alerting stakeholders and policy makers to pay attention to the growing epidemic is necessary.</p><p>For more detail, see the article in <em>Journal of Clinical and Translations Hepatology</em>:</p><p><a href="http://www.xiahepublishing.com/ArticleFullText.aspx?sid=2&amp;jid=1&amp;id=10.14218%2FJCTH.2017.00003">Rising Rate of Liver Transplantation in the Baby Boomer Generation with Non-alcoholic Steatohepatitis in the United States</a></p><p>About the Author:</p><p>Dr. Peter G. Traber is a gastroenterologist and hepatologist who has had multiple leadership positions in academia and industry. He was previously the Chief Executive Officer and Chief Medical Officer of Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and cancer.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=9733a657554b" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-liver-line/us-liver-transplantation-rates-on-the-rise-in-baby-boomers-with-nash-9733a657554b">US Liver Transplantation Rates on the Rise in Baby Boomers with NASH</a> was originally published in <a href="https://medium.com/the-liver-line">The Liver Line</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[NASH + Diabetes? Watch out for Cardiovascular Disease.]]></title>
            <link>https://medium.com/the-liver-line/nash-diabetes-watch-out-for-cardiovascular-disease-9f723739991d?source=rss-845d7f332ac4------2</link>
            <guid isPermaLink="false">https://medium.com/p/9f723739991d</guid>
            <category><![CDATA[diabetes]]></category>
            <category><![CDATA[nash]]></category>
            <category><![CDATA[fatty-liver]]></category>
            <category><![CDATA[cardiovascular-disease]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Peter G. Traber, M.D.]]></dc:creator>
            <pubDate>Tue, 31 Oct 2017 13:23:50 GMT</pubDate>
            <atom:updated>2018-07-25T19:08:04.312Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*22EJBglH82pKM-VEEYGLaQ.jpeg" /></figure><p>According to a <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367688/">study published in PLoS One</a>, if you have a medical history of early stage non-alcoholic steatohepatitis (NASH) or type 2 diabetes, you may have an increased risk of developing cardiovascular disease (CVD), doubling the risk of your overall mortality.</p><p>Researchers recently analyzed the data of 133,312 people with type 2 diabetes, including 1,998 that were also diagnosed with early-stage NASH. They found patients dually diagnosed were approximately 62 percent more likely to develop serious cardiovascular events such as strokes or recurrent CVD. The data also showed a 40 percent increase in CVD-related mortality, and a 41-fold increase in death due to hepatocellular carcinoma or liver cancer.</p><p>Often times when two or more conditions coexist, they augment the probability of developing additional complications. Since there are no approved therapies to combat NASH, researchers suggest adopting a healthier lifestyle to help lower your risks. It may be difficult to maintain, but it is achievable.</p><p>What’s more, <a href="https://www.medscape.com/viewarticle/887424">data presented</a> at The Liver Meeting 2017 in Washington D.C. showed that women with NASH are at equal risk for cardiovascular events as men with fatty liver disease. In the general population, women are protective for cardiovascular risk and less likely to experience CVD events. Investigators found this does not hold true in people with NASH.</p><h3>About the Author:</h3><p>Dr. Peter G. Traber is a gastroenterologist and hepatologist who has had multiple leadership positions in academia and industry. He was previously the Chief Executive Officer and Chief Medical Officer of Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and cancer.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=9f723739991d" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-liver-line/nash-diabetes-watch-out-for-cardiovascular-disease-9f723739991d">NASH + Diabetes? Watch out for Cardiovascular Disease.</a> was originally published in <a href="https://medium.com/the-liver-line">The Liver Line</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Can Thin People Get Fatty Liver Disease?]]></title>
            <link>https://medium.com/the-liver-line/can-thin-people-get-fatty-liver-disease-7e91e3ae3dde?source=rss-845d7f332ac4------2</link>
            <guid isPermaLink="false">https://medium.com/p/7e91e3ae3dde</guid>
            <category><![CDATA[fatty-liver-disease]]></category>
            <category><![CDATA[nash]]></category>
            <category><![CDATA[cirrhosis]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Peter G. Traber, M.D.]]></dc:creator>
            <pubDate>Tue, 24 Oct 2017 14:08:02 GMT</pubDate>
            <atom:updated>2018-07-25T19:09:48.388Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/570/1*QzCia6vhD7xvOqMXwUrIsQ.jpeg" /></figure><p>It is a common misconception that only overweight people get fatty liver disease (and NASH). One thing I have learned over my career in medicine is to always challenge such “common sense” assumptions with empirical research. While people who are overweight or obese are indeed at greater risk, thin people can also develop fatty liver disease, NASH and cirrhosis. This has come to be known as “lean NASH.”</p><p>The commonly accepted definition of obesity is a body mass index (BMI) of 30 or more. However, overall BMI is less important in determining risk for fatty liver disease than where the fat is located in the body. <a href="http://time.com/14407/the-hidden-dangers-of-skinny-fat/">Visceral fat</a>, when the fat is nestled in and around the organs of the belly, is more strongly linked to fatty liver disease and other metabolic disorders than fat in arms, legs, and other parts of the body. A person can easily have a BMI well below 30 and still have considerable visceral fat. Someone who is “metabolically obese, normal weight” will have many of the hallmarks of obesity, such as insulin resistance (requirement of higher insulin levels to control blood sugar), metabolic syndrome (high blood sugar, elevated fats and cholesterol in blood, high blood pressure, and excess body fat around the waist) and NASH.</p><p>A study published in 2012 showed that overall prevalence of fatty liver disease among obese individuals was 28 percent, while fatty liver disease was identifiable in 7 percent of the lean individuals tested. (Zobair M. Younossi, 2012) Yes, obese people had a greater incidence of fatty liver disease, but lean people still showed a surprisingly high prevalence of the disease.</p><p>The other surprising finding from this study was that lean NASH patients here in the U.S. tend to be Hispanic. It’s unclear whether it is culture, diet, genetics, or some completely different mechanism at work that makes those of Hispanic ancestry more likely to develop lean NASH. But, given the growth of the Hispanic population here in the U.S., lean NASH is likely to emerge in the coming decades as an important cause of chronic liver disease.</p><p>Ethnicity does seem to be one of the major determinants of lean NASH, which was first described by physicians in Asia. While metabolic syndrome has long been a problem in developed countries, it is an increasing problem in developing countries as well, even though the rate of obesity remains comparatively low. The prevalence of fatty liver disease among normal-weight individuals was <a href="http://www.news-medical.net/news/20160307/Absence-of-PEMT-enzyme-leads-to-development-of-fatty-liver-disease-and-tumours-in-thin-patients.aspx">reported </a>at 12% in Greece, 20% in India and 15% in China.</p><p>One analysis from 2013 suggests that lean NASH, as seen in Asia, is a distinct phenotype of NASH (Kausik Das, 2013). Asians, this study notes, show an inclination to develop metabolic syndrome at a lower BMI. One possible reason is that early malnutrition, either <em>in utero</em> or in early childhood, primes the body to store visceral fat more aggressively. The relative abundance of food in Asia today over the scarcities common only a few decades ago means that adults in China, India and other Asian countries are increasingly at risk of developing lean NASH.</p><p>I’ve called fatty liver disease a “hidden epidemic,” and lean NASH is even more so. It is easy to identify someone with a high body weight as being at risk for fatty liver disease, but less so for someone with lean NASH. We need a much better understanding of what causes lean NASH and how its presentation and biomarkers are distinct from the fatty liver disease and NASH seen in overweight patients.</p><p><strong>Works Cited</strong></p><ul><li>Kausik Das, A. C. (2013). Lean NASH: distinctiveness and clinical implication. <em>Hepatol Int , 7</em>(Supplement 2), S806 — S813.</li><li>Zobair M. Younossi, M. M. (2012, November). Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States. <em>Medicine, 91</em>(6), 319–227.</li></ul><p>About the Author:</p><p>Dr. Peter G. Traber is a gastroenterologist and hepatologist who has had multiple leadership positions in academia and industry. He was previously the Chief Executive Officer and Chief Medical Officer of Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and cancer.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7e91e3ae3dde" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-liver-line/can-thin-people-get-fatty-liver-disease-7e91e3ae3dde">Can Thin People Get Fatty Liver Disease?</a> was originally published in <a href="https://medium.com/the-liver-line">The Liver Line</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Dilemma of Treating NASH]]></title>
            <link>https://medium.com/the-liver-line/the-dilemma-of-treating-nash-26ea31ca4647?source=rss-845d7f332ac4------2</link>
            <guid isPermaLink="false">https://medium.com/p/26ea31ca4647</guid>
            <category><![CDATA[nash]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[fatty-liver-disease]]></category>
            <category><![CDATA[liver-fibrosis]]></category>
            <dc:creator><![CDATA[Peter G. Traber, M.D.]]></dc:creator>
            <pubDate>Tue, 10 Oct 2017 13:14:38 GMT</pubDate>
            <atom:updated>2018-07-25T19:11:03.053Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/595/1*RSg5fRL-GA6n7S8jXs684A.jpeg" /></figure><p>You may have seen <em>Newsweek</em>’s article on the growing impact of NASH, <a href="http://www.newsweek.com/2016/02/12/nash-deadly-liver-disease-obesity-big-pharma-421363.html"><em>NASH Is the 21st Century’s Looming Health Threat</em></a>. It’s a great article that vividly demonstrates the heartbreak of a NASH diagnosis and the shame and uncertainty faced by many patients.</p><blockquote><em>“I’m in this situation and not for lack of good diet and exercise,” says Sandra, whose father died of liver disease 30 years ago. “You can blame me if you like, but I’m doing what I’m supposed to do.”</em></blockquote><blockquote><em>“Unlike those who suffer from other serious illnesses, NASH patients have no colored wristband denoting awareness, no annual fundraising race, no built-in support network.”</em></blockquote><p>To me, this article has sparked the ethical issues surrounding treating NASH and fatty liver disease.</p><p>There was a hint in the <em>Newsweek</em> article of the debate over whether medical intervention in NASH is at some level a questionable endeavor, as it may make better sense for society to address the epidemic of obesity directly rather than try and deal with NASH. However, that argument doesn’t hold up under scrutiny, as nearly 50% of the U.S. population is overweight or obese by the standard definitions. If you refused to treat medical problems that arise due to, or are exacerbated by obesity that would mean you wouldn’t treat heart disease, diabetes, or osteoarthritis. Even cancer is closely related to obesity and diet. Additionally, as I will elaborate in another post, lean people can also suffer from NASH so it is a lot more complicated than just a fat liver.</p><p>I <a href="https://liverline.com/fatty-liver-disease-motivation-to-lose-weight-4b375351a010">wrote recently</a> about how fatty liver disease helped motivate me to lose weight. I believe that awareness and lifestyle changes, including weight loss and exercise, will always be the best ways for the medical community and healthcare in general to address the looming health crisis of fatty liver disease. A <a href="http://www.gastrojournal.org/article/S0016-5085%252815%252900496-5/pdf">recent study</a> showed that a 10% reduction of body mass resolved NASH in 90% of the patients in the study.</p><p>However, I also remain convinced that there will always be a need for direct drug intervention for NASH. Not everyone will respond to a regime of weight loss and increased exercise. NASH is a progressive disease, and the question becomes: At what stage do we resort to direct medical intervention rather than focusing on lifestyle changes?</p><p>There was a study published last year in <em>Hepatology </em>[1] that took patients with a biopsy-proven diagnosis of NASH and followed them for up to 33 years, with an average of 26 years. This study was done in Sweden, so it was easier to track patients for that length of time than it might be here in the U.S. The study showed that if a patient started with stage 1 or 2 disease (mild fibrosis), they had no increased risk of mortality in comparison to a reference group. Let me repeat: Fatty liver disease itself didn’t affect patient mortality at all when followed for up to 33 years! However, if a patient had advanced fibrosis — stage 3 and 4 disease — they had a 3.3 times increase in mortality over the reference population.</p><p>To me, this study suggests that it would be questionable to undertake a broad pharmaceutical approach to managing early-stage NASH. While a certain percentage of people will progress to advanced-stage NASH, we currently have no way of predicting which patient is at risk for this. Is it worth treating all 30 million people in the US with NASH, exposing them to the expense of the medication and its inevitable side effects when the treatment is not likely to have any impact on their long-term morbidity or mortality?</p><p>In contrast, we know that those who have NASH with advanced liver fibrosis do have an increase in morbidity and mortality related to NASH, so the more desirable approach might be to have a <a href="https://liverline.com/why-non-invasive-testing-is-needed-to-evaluate-fatty-liver-disease-5caa8a70d2c4">noninvasive test</a> that can distinguish early-stage NASH from late-stage NASH and a follow-up treatment with a drug proven to be efficacious for late-stage NASH.</p><ol><li><em>Journal of Hepatology, Volume 62, Supplement 2, April 2015, Pages S362–S363</em></li></ol><p>About the Author:</p><p>Dr. Peter G. Traber is a gastroenterologist and hepatologist who has had multiple leadership positions in academia and industry. He was previously the Chief Executive Officer and Chief Medical Officer of Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and cancer.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=26ea31ca4647" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-liver-line/the-dilemma-of-treating-nash-26ea31ca4647">The Dilemma of Treating NASH</a> was originally published in <a href="https://medium.com/the-liver-line">The Liver Line</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[A Brief Overview of Non-Invasive Testing in Liver Fibrosis]]></title>
            <link>https://medium.com/the-liver-line/a-brief-overview-of-non-invasive-testing-in-liver-fibrosis-46901565afac?source=rss-845d7f332ac4------2</link>
            <guid isPermaLink="false">https://medium.com/p/46901565afac</guid>
            <category><![CDATA[health]]></category>
            <category><![CDATA[liver-fibrosis]]></category>
            <category><![CDATA[liver-test]]></category>
            <category><![CDATA[nash]]></category>
            <category><![CDATA[liver-function]]></category>
            <dc:creator><![CDATA[Peter G. Traber, M.D.]]></dc:creator>
            <pubDate>Thu, 14 Sep 2017 13:22:25 GMT</pubDate>
            <atom:updated>2018-07-25T19:12:33.847Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/576/1*2-gDneX8CYsseatsAC0zCg.jpeg" /></figure><p>I <a href="https://liverline.com/why-non-invasive-testing-is-needed-to-evaluate-fatty-liver-disease-5caa8a70d2c4">wrote recently</a> about why we rely on liver biopsies for the diagnosis of NASH and liver fibrosis and the need for alternative, non-invasive tests that enable us to diagnose and track the progression the disease. Today I’d like to explore the different non-invasive tests being developed. There are two basic approaches: tests where blood (or serum) is tested for specific biomarkers, and the physical assessment of the liver using some form of imaging technology. I will use several prominent examples, but this will not cover every test being evaluated or available.</p><h4><strong>Serum tests</strong></h4><p>Serum tests (serum is the clear fluid that results after blood clots) are already commonly used in support of liver biopsy for a variety of liver diseases. A liver biopsy can indicate that a patient has viral hepatitis, for example, but there is no definitive way of knowing whether it’s hepatitis A, B, C, D or E without a blood test.</p><p>Might we be able to take the next step and use a blood test without resorting to a biopsy? These tests are problematic from several fundamental standpoints. One reason is that you don’t necessarily know without rigorous empirical research whether what’s in the serum is reflective of what’s in the liver. For example, the galectin-3 protein is markedly increased in the liver tissues in animal models with NASH, but galectin-3 levels in the serum aren’t reflective of what’s going on in the tissue. The same holds true for many of the thousands of other proteins involved.</p><p>Despite this, there are many researchers who are trying to devise sophisticated blood tests that provide much of the information found on a liver biopsy, which has been called a “liquid biopsy.” Researchers have been using proteomic approaches to examine the thousands of different proteins and modified proteins that are in the blood to see whether there are tests that reflect either the etiology or the degree of damage in the liver. In other cases, researchers are measuring all the products of metabolism, called metabolomics, to investigate the correlation with biopsy findings. People are also looking at microRNA circulating in the blood, as well as micro vesicles, which are small pieces of cells that break off and circulate in the blood. These approaches, while promising, are far from well-defined enough to be used in clinical medicine.</p><p>To simplify our discussion, let’s concentrate on some of the currently available blood tests that look to determine the degree of fibrosis in the liver. Many approaches have been tried on this problem, such as testing for single compounds like hyaluronic acid or compiling multiple different serum tests together to determine a combined score, such as FibroTest® or the ELF (Enhanced Liver Fibrosis) test. Research shows that many of these tests correlate in various ways between serum levels and the degree of fibrosis, but they’re not very precise. They can tell you whether there’s little fibrosis or a lot of fibrosis, but they can’t tell you all the different gradations in between. There’s no solid evidence that they’re going to be useful in their current iterations for testing the effect of a drug, because such effects are likely to be found in those gradations.</p><p>In my view the accuracy, precision and reliability of serum tests have not gotten to the point where they could be used as a reliable surrogate for a biopsy in clinical trials of antifibrotic drugs.</p><h4><strong>Physical assessment of the liver</strong></h4><p>Another possibility for non-invasive testing of the liver is through physical assessment, often through some form of diagnostic imaging. A fibrotic liver has very different physical characteristics than a normal liver, and some of this can be assessed by external means.</p><p>There are some imaging techniques that wouldn’t work for the assessment of liver fibrosis. CT (computed tomography) and standard ultrasound tests show liver tissue, but they are really only effective for examining the overall structure of the liver, its size, and whether there are tumors — not that useful for determining fibrosis.</p><p>A variety of ultrasound-based tests are the best studied methods for staging liver fibrosis, including FibroScan®, acoustic radiation force impulse imaging (ARFI), and real-time shear wave elastography (SWE). All of these tests essentially evaluate the stiffness of the liver, because the more fibrosis a patient has, the stiffer the liver becomes. <a href="http://www.myliverexam.com/en/lexamen-fibroscan.html">FibroScan</a>, developed by Echosens and approved for diagnostic use in the US, measures the speed of a mechanical pulse as it goes through the liver, which correlates that to stiffness and produces a pressure measurement, kilopascals. While FibroScan only measures a core of liver tissue, it is about 100 times bigger than the area measured by a liver biopsy. Liver disease and fibrosis are often not uniform throughout the entire liver, so analyzing a small sample might lead to either over- or underestimating the amount of fibrosis. FibroScan has many desirable characteristics for a test of liver fibrosis in that it is quick, inexpensive, can be done in a provider office setting, and is painless.</p><p><a href="http://appliedradiology.com/articles/mr-elastography-of-liver-disease-state-of-the-art">Magnetic resonance elastography</a>, or MRE, which is available from several manufacturers of imaging machines, uses low frequency vibrations applied to the patient. The MRI can pick up the perturbations as the pulse moves through the liver tissue. If the liver is very stiff, the pulse will move quickly. As with FibroScan, the results of MRE are reported in kilopascals and have been correlated to the degree of fibrosis as diagnosed through biopsy. It has the advantage of evaluating the entire liver, thereby eliminating sampling error of ultrasound based methods, and it simultaneously evaluates the liver for lesions such as tumors. While MRE compares favorably to FibroScan, and in some studies is more useful for staging fibrosis, it is much more expensive and less easily used in a clinical setting.</p><p>Software analyses of MRI data can be used to derive additional information. Such software-driven tests can measure various tissue parameters (so called multi-parametric tests) such as the amount of fluid, iron, fat and interstitial space — that is the space between the cells — in the liver. Since fibrosis and much of the inflammation are found in the interstitial space, this can be a useful test. Multi-parametric MRI software, for example <a href="http://perspectum-diagnostics.com/products/livermultiscan/">LiverMultiScan®</a> developed by Perspectum Diagnostics, combines all these elements to give a score that provides some indication of how much fibrosis there is in the liver. Similar to MRE, multi-parametric MRIs may be superior to a liver biopsy, because an MRI looks at the entire liver, slice by slice, while biopsy only samples 1/50,000th of the liver.</p><p>There is good correlation between LiverMultiScan and the results of liver biopsies (1), and a recent paper shows that it also correlates with patient outcomes (2). In other words, you can predict which patients are going to have bad outcomes from their liver disease based on the LiverMultiScan results. Furthermore, the results of a LiverMultiScan change in response to treatment. The most dramatic change reported was in a patient who had NASH with fibrosis and then underwent an intestinal bypass as a weight loss procedure. The patient’s LiverMultiScan score and fibrosis went down dramatically with the loss of weight. While this test is approved for diagnostic use in Europe and the U.S., we still need a lot more data before it would be accepted as a regulatory end point by FDA for drug approval, but it is a promising approach towards non-invasive evaluation.</p><p>Each of these three imaging methods are approved by regulatory agencies for diagnostic use and are currently available to physicians, mostly in selected locations. However, they have not been used in prospective, therapeutic clinical trials to assess the efficacy of a drug in liver fibrosis. Well controlled clinical trials will be necessary to validate these methods for use in drug approvals.</p><p>The goal is to get to the point where we can characterize the underlying fibrosis even more quantitatively and effectively as with a liver biopsy. When we’re able to do that, it will eliminate the risk and the pain associated with a liver biopsy, and enable us to evaluate the whole liver, not just 1/50,000th of it, multiple times with a patient.</p><p><strong>Reference List</strong></p><p>1. Banerjee R, Pavlides M, Tunnicliffe EM, Piechnik SK, Sarania N, Philips R, et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol 2014 Jan;60(1):69–77.</p><p>2. Pavlides M, Banerjee R, Sellwood J, Kelly CJ, Robson MD, Booth JC, et al. Multi-parametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol 2015 Oct 12.</p><p>About the Author:</p><p>Dr. Peter G. Traber is a gastroenterologist and hepatologist who has had multiple leadership positions in academia and industry. He was previously the Chief Executive Officer and Chief Medical Officer of Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and cancer.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=46901565afac" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-liver-line/a-brief-overview-of-non-invasive-testing-in-liver-fibrosis-46901565afac">A Brief Overview of Non-Invasive Testing in Liver Fibrosis</a> was originally published in <a href="https://medium.com/the-liver-line">The Liver Line</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Portal Hypertension and Why it’s Important in Liver Disease]]></title>
            <link>https://medium.com/the-liver-line/portal-hypertension-and-why-its-important-in-liver-disease-a47b193a8f1c?source=rss-845d7f332ac4------2</link>
            <guid isPermaLink="false">https://medium.com/p/a47b193a8f1c</guid>
            <category><![CDATA[liver-function]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[liver-fibrosis]]></category>
            <category><![CDATA[liver-cirrhosis]]></category>
            <category><![CDATA[nash]]></category>
            <dc:creator><![CDATA[Peter G. Traber, M.D.]]></dc:creator>
            <pubDate>Tue, 12 Sep 2017 17:55:08 GMT</pubDate>
            <atom:updated>2018-07-25T19:13:42.606Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/640/1*tXq-pLAsEGh55Xh0zLNkGA.jpeg" /></figure><p>Everyone has had the experience of having their blood pressure taken and knows the importance of a normal reading for good health. But most people have never heard of liver blood pressure. In fact, high liver blood pressure, called portal hypertension, is the primary reason for complications and death in patients with advanced chronic liver disease, called cirrhosis.</p><p>The liver has a dual blood supply, which is different than most parts of the body. For example the kidney, intestines, muscles and many other tissues have a single blood supply that comes directly through arteries via the heart. The liver has two blood supplies — one directly from an artery (similar to other tissues), and a second blood flow from the portal vein. The greater proportion of blood comes from the portal vein, which drains the blood from the abdominal organs (stomach, small and large intestine, pancreas, and spleen).</p><p>Portal blood brings nutrients and hormones from the gastrointestinal tract which are important for liver function and homeostasis of many bodily functions. After arterial and portal blood mixes and flows through the liver, it returns to the heart via the main vein in the body.</p><p>Liver disease has a profound effect on this blood flow. All chronic liver disease leads to scar formation, or fibrosis. Whether the disease is due to a virus, alcohol, or fat, this scar tissue accumulates in the liver, with the most advanced stage called cirrhosis. The fibrotic tissue of cirrhosis distorts the liver architecture, impeding liver blood flow and, as a result, the blood pressure in the portal vein increases — this is called portal hypertension.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*5Au6pMH-38PjXQBypiwLPg.png" /></figure><p>The figure shows what happens in portal hypertension. The increased pressure causes a certain type of vein dilations (similar to varicose veins or hemorrhoids), the most important of which are called esophageal varices. These dilated veins in the esophagus can burst and cause catastrophic bleeding. Another result of increased pressure is the build-up of fluid in the abdomen outside of the organs, called ascites, which is uncomfortable and can become infected. The increased pressure also results in additional vessels opening up, allowing blood to bypass the liver and enter directly into systemic circulation. Toxins that are normally removed by the liver gain direct access to the rest of the body and the brain, causing mental problems such as lethargy, confusion, and, in the worst cases, coma.</p><p>Portal hypertension does not occur with early stages of fibrosis but only when cirrhosis develops. In cirrhotic patients, the level of the portal pressure is directly related to the rate of cirrhotic complications and mortality. Additionally, if the portal pressure is decreased, the outcomes of patients are improved. This makes the portal pressure a potential surrogate for outcomes in clinical trials. If a drug therapy reduces portal pressure, it portends a better prognosis for the patient.</p><p>Measurement of portal pressure is not as simple as measuring systemic blood pressure. In fact, there is no direct way to measure portal pressure in clinical medicine. However, there is a minimally invasive radiology procedure that gives a very good estimate of portal pressure, called hepatic venous pressure gradient (HVPG). Rather than describe this technique, watch a <a href="https://www.youtube.com/watch?v=9cEOpr-MRL4">short video</a> of the procedure.</p><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fwww.youtube.com%2Fembed%2F9cEOpr-MRL4%3Ffeature%3Doembed&amp;url=http%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3D9cEOpr-MRL4&amp;image=https%3A%2F%2Fi.ytimg.com%2Fvi%2F9cEOpr-MRL4%2Fhqdefault.jpg&amp;key=d04bfffea46d4aeda930ec88cc64b87c&amp;type=text%2Fhtml&amp;schema=youtube" width="640" height="480" frameborder="0" scrolling="no"><a href="https://medium.com/media/844721278d27e8b0095b57bedbbb19d9/href">https://medium.com/media/844721278d27e8b0095b57bedbbb19d9/href</a></iframe><p>Measurement of HVPG to assess portal hypertension is a vital tool in evaluating potential therapies for liver cirrhosis. HVPG has been shown to be directly related to patient outcomes, making it a potential surrogate for drug registration trials.</p><p>About the Author:</p><p>Dr. Peter G. Traber is a gastroenterologist and hepatologist who has had multiple leadership positions in academia and industry. He was previously the Chief Executive Officer and Chief Medical Officer of Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and cancer.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a47b193a8f1c" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-liver-line/portal-hypertension-and-why-its-important-in-liver-disease-a47b193a8f1c">Portal Hypertension and Why it’s Important in Liver Disease</a> was originally published in <a href="https://medium.com/the-liver-line">The Liver Line</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Developing Tests to Assess Liver Function]]></title>
            <link>https://medium.com/the-liver-line/developing-tests-to-assess-liver-function-e8441dcf6667?source=rss-845d7f332ac4------2</link>
            <guid isPermaLink="false">https://medium.com/p/e8441dcf6667</guid>
            <category><![CDATA[liver-fibrosis]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[nash]]></category>
            <category><![CDATA[liver-cirrhosis]]></category>
            <category><![CDATA[liver-function]]></category>
            <dc:creator><![CDATA[Peter G. Traber, M.D.]]></dc:creator>
            <pubDate>Tue, 18 Jul 2017 13:21:46 GMT</pubDate>
            <atom:updated>2018-07-25T19:14:22.630Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*t6JbbQqudtJAz4yVFqU2HQ.jpeg" /></figure><p>Unlike other organs like the heart, lungs or kidneys, it is difficult to clinically assess liver function and the effect of liver disease or fibrosis on how the liver is working. As a result, we rely on physical assessments of liver structure (like biopsy and imaging tests) and indirect evaluations (like serum tests), to infer how disease may be affecting liver function. There are promising approaches being developed by two companies, HepQuant and Exalenz, for testing certain liver functions.</p><p>One of the functions of the liver is to extract bile acids out of serum and excrete them into the bile that subsequently enters the intestine. <a href="https://hepquant.com/">HepQuant</a>, headed by Dr. Greg Everson, has developed a test for evaluating how effectively the liver performs this function. As outlined in an <a href="https://liverline.com/using-bile-acid-as-the-basis-of-a-non-invasive-test-of-liver-function-in-chronic-liver-disease-735c0f090627">article </a>by Dr. Everson, HepQuant has generated data that demonstrate a linear correlation between the test’s results and various measures of liver disease, such as degree of fibrosis. The HepQuant test could be a very important test for evaluation of liver disease and as an endpoint in clinical trials in the future.</p><p>Another function of the liver is to metabolize drugs. A 13C-methacetin breath test developed by <a href="http://www.exalenz.com/toprightmenu/liver">Exalenz Bioscience</a> measures the metabolism of a drug. The company has shown a correlation of liver damage, cirrhosis and patient outcomes with the 13C-methacetin metabolic capacity, as discussed in an <a href="https://liverline.com/using-metabolic-breath-tests-to-assess-liver-disease-and-prognosis-186af944746d">article </a>by Dr. Yaron Ilan.</p><p>As these two tests are further refined and evaluated critically in the context of clinical trials, they could become important in diagnosing and monitoring the treatment of liver disease, because they aren’t just looking at the structure of the liver but instead actually give us a sense of how liver function is changing.</p><p>Clinical trials of prospective drug treatments of NASH should not only test the drug candidate based on the primary endpoint, such as liver biopsy, but at the same time also evaluate the relevance of non-invasive tests. From my perspective, this is something that all companies developing treatments for NASH and liver fibrosis should incorporate into the design of their clinical trials. No matter what the results for the candidate drugs, we should also take the opportunity to gain a better understanding of how the results of non-invasive tests correlate to the results of a liver biopsy and disease progression. That would add tremendous momentum in this area of medicine and with improved diagnosis, it would support the clinical use of these drugs when approved.</p><p>About the Author:</p><p>Dr. Peter G. Traber is a gastroenterologist and hepatologist who has had multiple leadership positions in academia and industry. He was previously the Chief Executive Officer and Chief Medical Officer of Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and cancer.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e8441dcf6667" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-liver-line/developing-tests-to-assess-liver-function-e8441dcf6667">Developing Tests to Assess Liver Function</a> was originally published in <a href="https://medium.com/the-liver-line">The Liver Line</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Healio: Coffee and Tea Lower Liver Stiffness; Liver Fibrosis Predictive of Increased Mortality]]></title>
            <link>https://medium.com/the-liver-line/healio-coffee-and-tea-lower-liver-stiffness-liver-fibrosis-predictive-of-increased-mortality-ca45043f079b?source=rss-845d7f332ac4------2</link>
            <guid isPermaLink="false">https://medium.com/p/ca45043f079b</guid>
            <category><![CDATA[nash]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[liver-fibrosis]]></category>
            <category><![CDATA[fatty-liver-disease]]></category>
            <dc:creator><![CDATA[Peter G. Traber, M.D.]]></dc:creator>
            <pubDate>Fri, 30 Jun 2017 13:34:44 GMT</pubDate>
            <atom:updated>2017-06-30T13:34:44.663Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/569/1*WNxYoQSeZNdeqU-oF8bfSA.jpeg" /></figure><p>We thought we would share some of the highlights from a recent <a href="http://www.healio.com/hepatology/steatohepatitis-metabolic-liver-disease/news/online/%7Bea7b710b-9a75-4701-836c-6f5a2d69beca%7D/5-recent-highlights-in-fibrosis-liver-stiffness">article in <em>Healio</em> </a>on key findings in liver fibrosis:</p><p>1. Frequent coffee, herbal tea intake have been linked to lower levels of liver stiffness.</p><p>2. Liver fibrosis scores were shown to be predictive of both increased liver disease mortality and overall mortality.</p><p>3. Doppler microvascular imaging was seen to predict the extent of liver fibrosis.</p><p>4. A retrospective study linked fibrosis stage and fat score to an increased risk for type 2 diabetes in NAFLD patients.</p><p>5. Magnetic resonance elastography (MRE) was successfully used to measure liver stiffness in pediatric patients with NAFLD</p><p>For more detail, see the article in <em>Healio</em>: <a href="http://www.healio.com/hepatology/steatohepatitis-metabolic-liver-disease/news/online/%7Bea7b710b-9a75-4701-836c-6f5a2d69beca%7D/5-recent-highlights-in-fibrosis-liver-stiffness">http://www.healio.com/hepatology/steatohepatitis-metabolic-liver-disease/news/online/%7Bea7b710b-9a75-4701-836c-6f5a2d69beca%7D/5-recent-highlights-in-fibrosis-liver-stiffness</a></p><p><strong>About the Author</strong></p><p>Dr. Peter G. Traber is a gastroenterologist and hepatologist who has had multiple leadership positions in academia and industry. He is currently Chief Executive Officer and Chief Medical Officer of Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and cancer.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ca45043f079b" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-liver-line/healio-coffee-and-tea-lower-liver-stiffness-liver-fibrosis-predictive-of-increased-mortality-ca45043f079b">Healio: Coffee and Tea Lower Liver Stiffness; Liver Fibrosis Predictive of Increased Mortality</a> was originally published in <a href="https://medium.com/the-liver-line">The Liver Line</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Can Drinking Coffee Cure NASH or Liver Fibrosis?]]></title>
            <link>https://medium.com/the-liver-line/can-drinking-coffee-cure-nash-or-liver-fibrosis-97562606b1c7?source=rss-845d7f332ac4------2</link>
            <guid isPermaLink="false">https://medium.com/p/97562606b1c7</guid>
            <category><![CDATA[health]]></category>
            <category><![CDATA[cirrhosis]]></category>
            <category><![CDATA[nash]]></category>
            <dc:creator><![CDATA[Peter G. Traber, M.D.]]></dc:creator>
            <pubDate>Tue, 27 Jun 2017 12:41:53 GMT</pubDate>
            <atom:updated>2018-07-25T19:17:55.106Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/600/1*yz0JWGCCFt4l85PmJ_8UNA.jpeg" /></figure><p>Every so often, there is a <a href="http://www.cnn.com/2016/02/20/health/coffee-liver-cirrhosis-irpt/">big splash in the news</a> about <a href="http://onlinelibrary.wiley.com/doi/10.1111/apt.13523/full">a study showing coffee drinking prevented cirrhosis</a>. Recently, <em>USA Today</em> reported that <a href="https://www.usatoday.com/story/news/nation-now/2017/06/09/drink-coffee-and-tea-they-may-good-your-liver/383958001/">both coffee and tea are good for your liver</a>. This always seems to strike a chord with people, and I’ve been getting a lot of questions about the study.</p><p>The short answer is, “Yes, drinking coffee and tea does seem to reduce your chances of liver scarring or developing cirrhosis.” However, it’s not that simple, so I wanted to dive into this news in a little more depth.</p><p>First, the relationship between coffee and cirrhosis is a topic that’s been examined in a number of different studies. For example, Stephen Harrison of Brooke Army Medical Center has published a paper that showed an inverse relationship between coffee consumption and NASH activity, i.e., the more coffee you drank, the milder your NASH.</p><p>The study highlighted by <em>USA Today</em> tracked the coffee- and tea-drinking habits of only 2,500 people, but the study referred to last year by <em>CNN</em> was a meta-analysis of many different studies — a study of studies, if you will. These kinds of studies are very common, having been used to establish all things we know about smoking and lung cancer, for example, or cholesterol and heart disease. In fact, one of the studies used in the meta-analysis was from a heart study group; once you have characterized a large set of individuals for one purpose, you can look at the data generated by that study for other things as well.</p><p>There’s a formal, scientific process for undertaking this sort of research that involves culling the entire literature to find every single paper that examines a particular issue — in this case cirrhosis and coffee consumption — and then using a list of criteria to choose the best papers for combining in a meta-analysis. Nine studies met the criteria for this particular meta-analysis, resulting in a total studied population of more than 430,000 individuals. This is a very large sample size, which allows for greater confidence in the findings.</p><p>The evidence seems clear that coffee consumption is associated with lower rates of the development of cirrhosis. The study established a dose-response relationship based on the number of cups of coffee consumed per day. To summarize the findings in everyday language, if you increase your consumption of coffee by two cups per day, you decrease your likelihood of developing cirrhosis by half, which is a pretty profound effect.</p><p>However, there are many things this study <em>doesn’t</em> tell us: How long do you have to drink coffee to have this effect? At what age do you have to start? If you have liver disease, will drinking coffee help you? If you are out drinking alcohol, will ending the night with a couple of cups of coffee protect your liver? Does the brand or strength of the coffee make a difference? No, that’s not what was studied here (despite what the <a href="http://www.cnn.com/2016/02/20/health/coffee-liver-cirrhosis-irpt/">headline in CNN’s story</a> might imply). It was simply an examination of how many people in this population have cirrhosis — or not –and how much coffee they say they drink. The relationship seems pretty strong, but this research doesn’t answer any of the other questions that people might have.</p><p>From a biochemical perspective it makes sense that coffee might have this effect. Many people tend to think of coffee as a dark liquid that has caffeine, but coffee is actually very complex, with hundreds of biologically active compounds. The vast majority of these compounds are taken up by the liver and are metabolized, just as the liver does with anything we eat and many drugs that we take.</p><p>This effect doesn’t extend to other caffeine-containing drinks. It appears to be the coffee that provides beneficial effects on the liver, not the caffeine. There have been studies comparing caffeinated with decaffeinated coffee, thereby isolating the effects of caffeine, and it appears likely that it’s not the caffeine that is the important factor. You can’t drink lots of Red Bull® and get the same effect.</p><p>What does this mean for patients and for physicians? To me, none of this precludes a common sense approach to liver health. However, coffee does seem to protect against liver disease, and there are other benefits that have been identified for coffee as well, including a reduction in all-cause mortality, neurological disease and some cancers, as recently reported for <a href="https://www.sciencedaily.com/releases/2016/04/160401073709.htm">colon cancer</a>. These benefits are balanced by some potential negative things about coffee. There are far fewer studies that suggest that coffee is bad for you, but there are some. For instance, there’s been a reported association with lung cancer. However, that effect is completely over-shadowed by tobacco use; people often smoke cigarettes while they’re drinking coffee, so it’s unclear that the coffee is to blame.</p><p>It’s possible we’ll never truly understand what it is about coffee that is responsible for this effect. There are people conducting experimental studies in animals and in cell lines, looking at the individual components of coffee in an attempt to determine which are having an effect on the fibrotic process. At some point, researchers may identify “compound X” within coffee, but we are a long way from turning this connection into something that would play an active role in the treatment of fibrosis and cirrhosis.</p><p>On balance, as a physician looking at these data, I think it makes sense to advise people who enjoy coffee to drink coffee. If coffee doesn’t bother you, and you’d like to have two or three cups a day, go ahead. It may benefit your liver, and there’s nothing like a good cup of coffee. That said, I wouldn’t think it right for a physician to start writing prescriptions for drinking coffee.</p><p>About the Author:</p><p>Dr. Peter G. Traber is a gastroenterologist and hepatologist who has had multiple leadership positions in academia and industry. He was previously the Chief Executive Officer and Chief Medical Officer of Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and cancer.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=97562606b1c7" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-liver-line/can-drinking-coffee-cure-nash-or-liver-fibrosis-97562606b1c7">Can Drinking Coffee Cure NASH or Liver Fibrosis?</a> was originally published in <a href="https://medium.com/the-liver-line">The Liver Line</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Cirrhosis Linked to Higher Risk of Stroke]]></title>
            <link>https://medium.com/the-liver-line/cirrhosis-linked-to-higher-risk-of-stroke-2bb1bbfbd791?source=rss-845d7f332ac4------2</link>
            <guid isPermaLink="false">https://medium.com/p/2bb1bbfbd791</guid>
            <category><![CDATA[stroke]]></category>
            <category><![CDATA[liver-fibrosis]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[liver-cirrhosis]]></category>
            <dc:creator><![CDATA[Peter G. Traber, M.D.]]></dc:creator>
            <pubDate>Thu, 15 Jun 2017 13:23:12 GMT</pubDate>
            <atom:updated>2017-06-15T15:10:45.986Z</atom:updated>
            <content:encoded><![CDATA[<p>A <a href="http://www.medpagetoday.com/neurology/strokes/65811">retrospective cohort study</a> of 1,618,059 Medicare patients showed that people with cirrhosis have a significantly increased risk of stroke, particularly hemorrhagic stroke. The association was seen regardless of cirrhosis type. However, there was no association found between, non-cirrhotic liver disease and stroke.</p><p>“These data ‘challenge the prevailing notion that cirrhosis is protective against stroke, an idea which can be traced to autopsy studies decades old,’ [Neal S. Parikh, MD, of Weill Cornell Medicine and New York-Presbyterian Hospital in New York City] told <em>MedPage Today</em>.”</p><p>See the complete <em>MedPage Today</em> story at <a href="http://www.medpagetoday.com/neurology/strokes/65811">http://www.medpagetoday.com/neurology/strokes/65811</a></p><p><strong>About the Author</strong></p><p>Dr. Peter G. Traber is a gastroenterologist and hepatologist who has had multiple leadership positions in academia and industry. He is currently Chief Executive Officer and Chief Medical Officer of Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and cancer.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2bb1bbfbd791" width="1" height="1" alt=""><hr><p><a href="https://medium.com/the-liver-line/cirrhosis-linked-to-higher-risk-of-stroke-2bb1bbfbd791">Cirrhosis Linked to Higher Risk of Stroke</a> was originally published in <a href="https://medium.com/the-liver-line">The Liver Line</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>